{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-007916","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.230670+00:00","generated_at":"2026-06-18T00:40:23.645366+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Eton Q4 2022: product revenue +220% YoY, net income positive; CEO sees 2023 doubling","bullets":["Q4 net revenue $8.5M (incl. $5M milestone); product/royalty $3.5M (+220% YoY, +9% QoQ).","Net income $0.9M ($0.04 diluted EPS); gross profit $6.4M; cash $16.3M at Dec 31, 2022.","Eighth straight sequential product revenue growth; CEO expects at least 2x product/royalty revenue in 2023.","Expanded rare disease sales force to 12 specialists; Betaine launch imminent; Dehydrated Alcohol NDA action date June 27, 2023.","Acquired ET-600 (rare pediatric endocrinology); ET-400 NDA expected by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-007916","json":"https://secwatch.observer/filing/0001493152-23-007916.json","markdown":"https://secwatch.observer/filing/0001493152-23-007916.md","text":"https://secwatch.observer/filing/0001493152-23-007916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000149315223007916/0001493152-23-007916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000149315223007916/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:40:23.645366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"438e9a8f8994d46aeb735f3772a90e34d06941c0","claim":"Eton Pharmaceuticals, Inc. reported financial results for fourth quarter ended December 31, 2022.","evidence_excerpt":"Net income for the fourth quarter of 2022 was $0.9 million or $0.04 per basic and diluted share compared to a net income of $1.0 million or $0.04 per diluted share in the prior year period","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710340/000149315223007916/0001493152-23-007916-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9dbacb2cd0b3fc80995010260d3c5f8d0bee699c","claim":"Eton Pharmaceuticals, Inc. reported fourth quarter and year ended December 31, 2022 results: revenue $8.5 million, net income $0.9 million, EPS $0.04 per basic and diluted share.","evidence_excerpt":"Net revenues for the fourth quarter of 2022 were $8.5 million compared with $6.1 million in the prior year period","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710340/000149315223007916/0001493152-23-007916-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$8.5 million"},{"label":"Net income","value":"$0.9 million"},{"label":"EPS","value":"$0.04 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}